144 related articles for article (PubMed ID: 27114913)
21. Overview of the mucopolysaccharidoses.
Muenzer J
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v4-12. PubMed ID: 22210669
[TBL] [Abstract][Full Text] [Related]
22. Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation.
Honjo RS; Vaca ECN; Leal GN; Abellan DM; Ikari NM; Jatene MB; Martins AM; Kim CA
BMC Med Genet; 2020 Feb; 21(1):37. PubMed ID: 32075597
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.
Furujo M; Kosuga M; Okuyama T
Mol Genet Metab Rep; 2017 Dec; 13():69-75. PubMed ID: 28983456
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
26. Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI.
Fung EB; Johnson JA; Madden J; Kim T; Harmatz P
J Pediatr Rehabil Med; 2010; 3(1):13-23. PubMed ID: 20617160
[TBL] [Abstract][Full Text] [Related]
27. Psychobehavioral factors and family functioning in mucopolysaccharidosis: preliminary studies.
do Valle DA; Bara TDS; Furlin V; Santos MLSF; Cordeiro ML
Front Public Health; 2024; 12():1305878. PubMed ID: 38327584
[TBL] [Abstract][Full Text] [Related]
28. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots.
Hein LK; Meikle PJ; Dean CJ; Bockmann MR; Auclair D; Hopwood JJ; Brooks DA
Clin Chim Acta; 2005 Mar; 353(1-2):67-74. PubMed ID: 15698592
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of dipeptidyl peptidase-IV (DPP-IV) activity in patients with mucopolysaccharidoses types I and II on enzyme replacement therapy - Results of a pilot study.
Hetmańczyk K; Bednarska-Makaruk M; Kierus K; Murawska-Izdebska S; Piekutowska-Abramczuk D; Pilch B; Tylki-Szymańska A; Ługowska A
Clin Biochem; 2016 Apr; 49(6):458-462. PubMed ID: 26592960
[TBL] [Abstract][Full Text] [Related]
30. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
31. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
Schlander M; Beck M
Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
[TBL] [Abstract][Full Text] [Related]
32. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
33. Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome.
Eisengart JB; Jarnes J; Ahmed A; Nestrasil I; Ziegler R; Delaney K; Shapiro E; Whitley C
Mol Genet Metab Rep; 2017 Dec; 13():64-68. PubMed ID: 28983455
[TBL] [Abstract][Full Text] [Related]
34. Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: insight into mucopolysaccharidosis type VI.
Saito S; Ohno K; Sugawara K; Sakuraba H
Mol Genet Metab; 2008 Apr; 93(4):419-25. PubMed ID: 18248830
[TBL] [Abstract][Full Text] [Related]
35. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
[TBL] [Abstract][Full Text] [Related]
37. Short Communication Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings.
Franco JF; Soares DC; Torres LC; Leal GN; Cunha MT; Honjo RS; Bertola DR; Kim CA
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26910003
[TBL] [Abstract][Full Text] [Related]
38. Mucopolysaccharidoses and the eye.
Ashworth JL; Biswas S; Wraith E; Lloyd IC
Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358
[TBL] [Abstract][Full Text] [Related]
39. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
Muenzer J
Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
[TBL] [Abstract][Full Text] [Related]
40. Mutations in ARSB in MPS VI patients in India.
Mathew J; Jagadeesh SM; Bhat M; Udhaya Kumar S; Thiyagarajan S; Srinivasan S
Mol Genet Metab Rep; 2015 Sep; 4():53-61. PubMed ID: 26937411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
